|
FR2692265B1
(fr)
|
1992-05-25 |
1996-11-08 |
Centre Nat Rech Scient |
Composes biologiquement actifs de type phosphotriesters.
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
JP4236812B2
(ja)
|
1997-09-12 |
2009-03-11 |
エクシコン エ／エス |
オリゴヌクレオチド類似体
|
|
KR20020013513A
(ko)
|
1999-03-18 |
2002-02-20 |
추후제출 |
Ｘｙｌｏ-ｌｎａ 유사체
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
EP1481983A4
(en)
|
2002-02-13 |
2008-04-02 |
Takeshi Imanishi |
NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF
|
|
EP1572713A4
(en)
|
2002-08-14 |
2006-05-24 |
Pharmacia Corp |
ANTISENSE MODULATION OF ACYL-COA SYNTHETASE 1 EXPRESSION
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
WO2004063331A2
(en)
|
2003-01-03 |
2004-07-29 |
Gencia Corporation |
SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA
|
|
EP1661905B9
(en)
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Novel artificial nucleic acids of n-o bond crosslinkage type
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
CA2927045A1
(en)
|
2006-10-03 |
2008-04-10 |
Muthiah Manoharan |
Lipid containing formulations
|
|
EP2215229B1
(en)
|
2007-11-28 |
2015-07-08 |
National University Corporation Tokyo Medical and Dental University |
System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron
|
|
EP2238249A2
(en)
|
2007-12-07 |
2010-10-13 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of mcl-1
|
|
EP2264167B1
(en)
|
2008-03-31 |
2016-10-12 |
National Institute of Advanced Industrial Science and Technology |
Double-stranded lipid-modified rna having high rna interference effect
|
|
CA2721183C
(en)
|
2008-04-11 |
2019-07-16 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
JP2010184879A
(ja)
|
2009-02-10 |
2010-08-26 |
Univ Of Tokyo |
抗筋萎縮剤
|
|
CA2778171C
(en)
|
2009-10-29 |
2017-07-25 |
Osaka University |
Bridged artificial nucleoside and nucleotide
|
|
EP2327783A1
(en)
|
2009-11-27 |
2011-06-01 |
Universitätsklinikum Freiburg |
Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
|
|
AU2011235276B2
(en)
|
2010-03-29 |
2015-09-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
|
|
EP2576785A4
(en)
|
2010-06-04 |
2014-12-24 |
Univ Texas |
METABOLIC CHANGE BY ME-378
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
SI3366775T2
(sl)
|
2011-11-18 |
2025-12-31 |
Alnylam Pharmaceuticals, Inc. |
Modificirana sredstva RNAI
|
|
EP3730618A1
(en)
|
2011-11-18 |
2020-10-28 |
Alnylam Pharmaceuticals, Inc. |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
JP2015502365A
(ja)
|
2011-12-12 |
2015-01-22 |
オンコイミューニン，インコーポレイティド |
オリゴヌクレオチドのイン−ビボ送達
|
|
JP6112569B2
(ja)
|
2011-12-16 |
2017-04-12 |
国立大学法人 東京医科歯科大学 |
キメラ２重鎖核酸
|
|
EA030211B1
(ru)
|
2012-04-25 |
2018-07-31 |
Регьюлэс Терапьютикс Инк. |
Соединения на основе микрорнк и способы модулирования активности mir-21
|
|
US9163235B2
(en)
|
2012-06-21 |
2015-10-20 |
MiRagen Therapeutics, Inc. |
Inhibitors of the miR-15 family of micro-RNAs
|
|
US20150337002A1
(en)
|
2013-01-15 |
2015-11-26 |
Shionogi & Co., Ltd. |
Nucleoside and nucleotide having sulfonamide structure
|
|
WO2014126229A1
(ja)
|
2013-02-18 |
2014-08-21 |
塩野義製薬株式会社 |
含窒素複素環構造を有するヌクレオシド及びヌクレオチド
|
|
JP6482475B2
(ja)
|
2014-01-07 |
2019-03-13 |
レナセラピューティクス株式会社 |
アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
|
|
US20170051286A1
(en)
|
2014-05-01 |
2017-02-23 |
Larry J. Smith |
METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
|
|
US10264976B2
(en)
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
|
US10610564B2
(en)
*
|
2015-02-26 |
2020-04-07 |
Stc.Unm |
IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
|
|
EP3603648B1
(en)
|
2017-03-29 |
2025-09-17 |
Shionogi & Co., Ltd |
Complex of nucleic acid medicine and multibranched lipid
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|